/ CORRECTION - Vicor Technologies CEO Discusses New Developments With CEOCFO

BOCA RATON, FL, May 27 (MARKET WIRE) --
In the news release, "Vicor Technologies CEO Discusses New Developments
With CEOCFO," issued earlier today by Vicor Technologies, Inc. (OTCBB:
VCRT), we are advised by the company that the link in the seventh
paragraph should actually be
http://ceocfointerviews.com/interviews/VCRT-Vicor09.htm rather than
"http://ceocfointerviews.com/interviews/VCRT-Vicor.htm" as originally
issued. Complete corrected text follows.

BOCA RATON, FL -- May 22, 2009 -- Vicor Technologies, Inc. (OTCBB: VCRT)
today announced that David H. Fater, President and CEO, participated in a
comprehensive, in-depth interview with online publication CEOCFO. Vicor
Technologies is a development-stage biotechnology company focused on the
commercialization of non-invasive diagnostic products using its patented,
proprietary PD2i algorithm and software to analyze heart rate variability
and identify individuals at risk of sudden cardiac death, trauma victims
requiring immediate life saving intervention, and diabetics at risk of
developing diabetic autonomic neuropathy.

In the interview, Mr. Fater discussed recent activities involving Vicor's
three diagnostic products. The Company received FDA 510(k) marketing
approval late last year for its PD2i Analyzer. Under an OEM agreement with
a leading manufacturer of medical diagnostic products linked to PCs, Vicor
has developed the Vicor PD2i Cardiac Analyzer EKG, a state-of-the-art
diagnostic tool to measure heart rate variability. Vicor will co-market
the new PD2i Cardiac Analyzer ECG and receive revenue from both the sale
of the equipment and from analysis of the test results. The PD2i Analyzer
is also currently in clinical trials to establish it as a diagnostic tool
for diabetic autonomic neuropathy. The American Diabetes Association
recommends that diabetics -- approximately 18 million in the U.S. alone
-- receive annual screenings for this "silent killer" disease.

Under a collaborative research and development agreement (CRADA) with the
U.S. Army Institute for Surgical Research, Vicor is developing the PD2i VS
(Vital Sign) for use in triaging combat and civilian trauma victims. Mr.
Fater anticipates FDA approval for a modification to Vicor's existing
510(k) for application in the trauma and emergency response arenas later
this year, with revenue generation expected shortly thereafter.

Vicor's PD2i CA (Cardiac Analyzer), which is currently involved in
multiple clinical trials, accurately identifies individuals at high risk
of suffering sudden cardiac death (SCD) within a six-month time frame and
could benefit from an implantable cardioverter defibrillator (ICD). Mr.
Fater anticipates FDA approval for an application to risk stratify SCD
during the second half of 2009.

"This is a very exciting time for Vicor," stated Mr. Fater. "Given the
relatively short regulatory process of modifying our existing 510(k) and
the ease of use of our product platform, we expect revenue generation to
commence during the second half of this year. We believe Vicor is
extremely well-positioned to grow revenues and profits quickly, as each of
our products addresses a vital need of sizable at-risk populations. This
is especially true of the diagnostic situation for SCD, which has been
described as 'in chaos' by cardiologists," Mr. Fater concluded.

With as many as 500,000 reported cases annually, SCD is a leading cause of
death in the U.S. Approximately 12 million U.S. cardiac patients meet the
criteria for being at an elevated risk of SCD and receiving an ICD as a
preventive measure. Recent studies reveal that 76 percent of ICDs
implanted using currently-available criteria never deliver an appropriate
shock, suggesting a lack of true need in those patients and resulting in
unnecessary ICD implantations with all of the associated health risks and
costs. Conversely, only 20-30 percent of those who do have an episode of
SCD would have met the current criteria for an ICD, leaving the remaining
70-80 percent unprotected.

Mr. Fater's CEOCFO interview may be accessed directly at:
http://ceocfointerviews.com/interviews/VCRT-Vicor09.htm

About Vicor Technologies, Inc.

Vicor Technologies is a development-stage biotechnology company creating
innovative non-invasive diagnostics employing its patented, proprietary
point correlation dimension algorithm (PD2i) and software. The PD2i is a
deterministic, non-linear measure that accurately evaluates biological
signals to predict with high sensitivity and high specificity future
pathological events in target populations.

Vicor currently has three products employing the PD2i algorithm. The PD2i
Analyzer, now in commercialization, measures heart rate variability. The
PD2i VS (Vital Sign), in clinical trials under a collaborative effort with
the U.S. Army Institute for Surgical Research
(http://www.usaisr.amedd.army.mil/), risk stratifies combat and civilian
trauma victims. The PD2i CA (Cardiac Analyzer), in multiple clinical
trials, identifies patients at risk of suffering sudden cardiac death.

Vicor anticipates additional applications employing the PD2i to enable
early detection and risk stratification for a variety of other disorders
and diseases. Additional information is available at www.vicortech.com.

About CEOCFO

CEOCFO is a daily online publication/marketing engine featuring interviews
and news of publicly traded and venture capital companies listed on the
U.S. (NYSE, NASDAQ, AMEX, OTC: BB, Pink Sheets), Canadian (TSX, TSX-V),
and international stock exchanges. To access the website, please go to
www.CEOCFO.biz.

The appearance of name-brand institutions or products in this media
release does not constitute endorsement by the U.S. Army Medical Research
and Materiel Command, the Department of the Army, Department of Defense
or the U.S. Government of the information, products or services contained
therein.

Caution Regarding Forward-Looking Statements

Forward-looking
statements in this press release are based on current plans and
expectations that are subject to uncertainties and risks, which could
cause our future results to differ materially. The following factors,
among others, could cause our actual results to differ: our ability to
obtain FDA approval of the PD2i VS for military and civilian applications
and the PD2i Cardiac Analyzer; our ability to continue to receive
financing sufficient to complete the critical clinical trials; our
ability to continue as a going concern; our ability to successfully
develop products based on our technologies; our ability to obtain and
maintain adequate levels of third-party reimbursement for our products;
the impact of competitive products and pricing; our ability to receive
regulatory approval for our products; the ability of third-party contract
research organizations to perform preclinical testing and clinical trials
for our technologies; the ability of third-party manufacturers to
manufacture our products; our ability to retain the services of our key
personnel; our ability to market and sell our products successfully; our
ability to protect our intellectual property; product liability; changes
in federal income tax laws and regulations; general market conditions in
the medical device and pharmaceutical industries; and changes in laws and
regulations and other matters that are described in Vicor's Annual Report
on Form 10-K for the fiscal year ended Deecmber 31, 2008 and subsequent
filings with the Securities and Exchange Commission. Forward-looking
statements in this press release speak only as of the date of the press
release, and we assume no obligation to update forward-looking statements
or the reasons why actual results could differ.

Release 09-08

Corporate Contact
David H. Fater
Vicor Technologies, Inc.
561.995.7313
dfater@vicortech.com

Media Contact
Robin Schoen
Robin Schoen Public Relations
215.504.2122
schoenpr@comcast.net

Investor Contact
Richard Moyer
Cameron Associates
212.554 5466
richard@cameronassoc.com

Copyright 2009, Market Wire, All rights reserved.

-0-